New study seeks safe dose of cancer drug for patients with liver issues
NCT ID NCT04617522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing the drug sacituzumab govitecan in 30 people with advanced solid tumors who also have moderate liver impairment. The main goal is to find a safe starting dose by monitoring side effects and how the drug moves through the body. Participants receive the drug intravenously, and the study will track any serious reactions or lab changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan (a drug that combines an antibody with chemotherapy to target cancer cells)
What this could lead to
If successful, this study could help doctors find a safe starting dose of sacituzumab govitecan for patients with advanced cancer and liver problems, potentially expanding treatment options.
What could go wrong
This is a very early phase 1 trial with only 30 participants, so results may not apply to everyone. The drug may still cause serious side effects, especially in people with liver impairment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
-
Christiana Care Health Services
RECRUITINGNewark, Delaware, 19713, United States
-
Hospital Universitario Virgen del Rocío
RECRUITINGSeville, 41013, Spain
-
Institut Bergonie Medical Oncology
RECRUITINGBordeaux, 33000, France
-
Institut Català d'Oncologia - L'Hospitalet de Llobregat
RECRUITINGBarcelona, 08908, Spain
-
Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain
RECRUITINGSaint-Herblain, France
-
Instituto Europeo di Oncologia
RECRUITINGMilan, 20141, Italy
-
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
RECRUITINGNaples, 80131, Italy
-
NEXT Austin
WITHDRAWNAustin, Texas, 78758, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
Oncology Consultants, P.A.
RECRUITINGHouston, Texas, 77030, United States
-
Pacific Shores Medical Group
SUSPENDEDLong Beach, California, 90813, United States
-
Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
-
The University of Texas M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Maryland
RECRUITINGBaltimore, Maryland, 21201, United States